BioInvest In The News

Opinion: Four reasons for investors to buy biotechnology stocks now (05-20-2016)
Pacira: Safer than Opioids? (05-19-2016)
Opinion: Dozens of biotech companies are ‘free’ for investors’ taking (2-16-2016)
Top Picks 2016: Pharmaceuticals (1-28-2016)
Top Picks 2016: Anthera (1-15-2016)
2015's Top Performers (1-12-2016)
Company Updates
Ziopharm (ZIOP) (5-16-16)

Ziopharm (ZIOP) (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ZIOP – Shows Rather Impressive Preclinical Data at ASGCT, Up Next Human Data at ASCO.
ZIOP was front and center at the 2016 Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington D.C. last week. The company presented exciting preclinical data for IL-12 in combo with a PD-1 that showed 100% survival. The non-viral Sleeping Beauty (SB) system was also on display. Read more…

Novavax Update (5-16-16)

Novavax Update (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – NVAX – Q1 Call – Preparing For The Launch Of The RSV Vaccine With Partners In The Wings; We Are In The Zone Read more…

Anthera Update (5-16-16)

Anthera Update (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ANTH — As IgAN Data Nears, The Case For A Reduction In Proteinuria. With Anthera shortly delivering its first new clinical trial results in a long time, the implications of the IgAN data, in our opinion the implications of the IgAN data, while not yet valued by investors, are many. Read more…